StreetInsider.com News Articles

Form 6-K Polyrizon Ltd. For: Mar 10

Tue, 10 Mar 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260310/26135939.html

Form 6-K Polyrizon Ltd. For: Mar 10

Tue, 10 Mar 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260310/26135939.html

Polyrizon completes GMP manufacturing for planned US clinical trial

Tue, 10 Mar 2026 07:56:37 -0400

Polyrizon Ltd. (NASDAQ: PLRZ) announced the completion of Good Manufacturing Practice manufacturing of clinical trial material for its lead product candidate. The biotechnology company, which develops intranasal administration solutions, produced the GMP batch through its manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S.

The clinical trial material will support a planned clinical study in the United States later this year. The GMP batch followed two prior development batches that demonstrated batch-to-batch consistency and product stability, according to the company's statement.

The material was manufactured in compliance with applicable GMP standards and will be used for upcoming clinical activities and regulatory submissions related to

Polyrizon completes GMP manufacturing for planned US clinical trial

Tue, 10 Mar 2026 07:56:37 -0400

The material was manufactured in compliance with applicable GMP standards and will be used for upcoming clinical activities and regulatory submissions related to

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Tue, 10 Mar 2026 07:55:00 -0400

Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.

This milestone follows the Company’s previously announced manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S, a leading global GMP CDMO, established to support the supply of clinical trial material for Polyrizon’s clinical development program.

The GMP manufacturing milestone represents a key step in Polyrizon’s clinical development program and supports the

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Tue, 10 Mar 2026 07:55:00 -0400

The GMP manufacturing milestone represents a key step in Polyrizon’s clinical development program and supports the

Form SCHEDULE 13G/A Polyrizon Ltd. Filed by: L.I.A. Pure Capital Ltd

Mon, 09 Mar 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260309/26132588.html

Form SCHEDULE 13G/A Polyrizon Ltd. Filed by: L.I.A. Pure Capital Ltd

Mon, 09 Mar 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260309/26132588.html

Form 6-K Polyrizon Ltd. For: Feb 26

Thu, 26 Feb 2026 08:14:00 -0400

si-local-file:///var/storage/secattach/20260226/26064967.html

Form 6-K Polyrizon Ltd. For: Feb 26

Thu, 26 Feb 2026 08:14:00 -0400

si-local-file:///var/storage/secattach/20260226/26064967.html

Polyrizon naloxone formulation shows improved nasal deposition in study

Thu, 26 Feb 2026 08:13:28 -0400

Polyrizon Ltd. (NASDAQ: PLRZ) announced results from a comparative study showing its naloxone formulation achieved higher nasal deposition compared to a commercial reference product. The study was conducted at the University of Parma's Biopharmanet-TEC research center under Prof. Fabio Sonvico's supervision.

The evaluation used a validated silicone nasal cast model combined with quantitative image analysis. Polyrizon's formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate region, compared to 79.6% for the commercial reference product.

The company's formulation also showed 5.4% deposition in the lower turbinate region versus 20.4% for the commercial product. The upper nasal region targeted by Polyrizon's formulation

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Thu, 26 Feb 2026 08:12:00 -0400

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product.

The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies.

The evaluation was performed using a validated silicone nasal cast model (Koken® LM-005) combined with quantitative image

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Thu, 26 Feb 2026 08:12:00 -0400

The evaluation was performed using a validated silicone nasal cast model (Koken® LM-005) combined with quantitative image

LDB Capital Corp. Announces Definitive Agreement for Proposed Qualifying Transaction with Eventer Technologies Ltd.